FORMYCON AG news, videos and press releases
For more news please use our advanced search feature.
FORMYCON AG - More news...
FORMYCON AG - More news...
- EQS-News: Formycon reports nine-month results for 2024 and continues growth trajectory with further operational successes
- EQS-News: Formycon invites to earnings call on the nine-month results 2024 and announces participation in international investor conferences
- EQS-News: Formycon receives positive CHMP opinion for FYB203 (aflibercept), a biosimilar candidate to Eylea® under the tradenames AHZANTIVE® and Baiama®
- EQS-Adhoc: Aflibercept-Biosimilar FYB203 / AHZANTIVE®/ Baiama® receives positive CHMP Opinion from EMA
- EQS-News: Formycon extends Management Board contract for CEO Dr. Stefan Glombitza until 2027 and receives admission to trading in the Prime Standard
- EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
- EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
- EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
- EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
- EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
- EQS-News: Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
- EQS-News: Formycon reports a strong first half-year with multiple milestones achieved
- EQS-News: Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
- EQS-Adhoc: Formycon AG increases its outlook for the 2024 fiscal year
- EQS-News: Formycon announces start of clinical phase III trial for Keytruda® biosimilar candidate FYB206
- EQS-News: Formycon and Fresenius Kabi receive positive CHMP opinion for FYB202 (Ustekinumab), a biosimilar candidate to Stelara®
- EQS-Adhoc: Stelara® Biosimilar Candidate FYB202 (Ustekinumab) receives positive CHMP opinion from EMA
- EQS-News: Formycon receives FDA approval for FYB203/AHZANTIVE®1) (aflibercept-mrbb), a biosimilar to Eylea®2)
- EQS-Adhoc: FDA grants approval for Eylea®1) biosimilar FYB203/AHZANTIVE®2) (aflibercept-mrbb)
- EQS-News: Formycon reports on the results of the Annual General Meeting
- EQS-News: Formycon starts clinical development program for FYB206, a biosimilar candidate for immuno-oncology blockbuster drug Keytruda
- EQS-News: MS Pharma becomes Partner for the Commercialization of FYB203, Formycon’s Biosimilar Candidate to Eylea® (Aflibercept), in the MENA Region
- EQS-News: Formycon reports on successful operating business and financial figures for the first quarter of 2024
- EQS-News: Formycon invites to the Annual General Meeting on June 12, 2024 in Munich
- EQS-News: Formycon hosts conference call on the results of the first quarter 2024
- EQS-News: Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance
- EQS-News: Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024
- EQS-News: Convincing overall performance - Formycon reports preliminary results for the financial year 2023 and exceeds forecast
- EQS-Adhoc: Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year
- EQS-News: Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®)
